a b s t r a c t S-Ribosylhomocysteinase (LuxS) catalyzes the cleavage of the thioether bond of S-ribosylhomocysteine (SRH) to produce homocysteine and 4,5-dihydroxy-2,3-pentanedione (DPD), which is the precursor of type 2 autoinducer for bacterial cell-cell communication. In this work, we have synthesized several SRH analogues modified at the ribose C3 position as potential inhibitors of LuxS. While removal or methylation of the C3-OH resulted in simple competitive inhibitors of moderate potency, inversion of the C3 stereochemistry or substitution of fluorine for C3-OH resulted in slow-binding inhibitors of improved potency. The most potent inhibitor showed a K Ã I value of 0.43 lM.
Introduction
The bacterial enzyme 5 0 -methylthioadenosine/S-adenosylhomocysteine (SAH) nucleosidase (MTAN, EC 3.2.2.9) catalyzes the depurination of SAH to form adenine and S-ribosyl-L-homocysteine (SRH) ( Fig. 1 ). 1 Encoded by the pfs gene, MTAN is involved in several bacterial processes including polyamine biosynthesis, quorum sensing (QS), methyl-transfer reactions, and adenine and methionine salvage. 2 SRH is subsequently converted to L-homocysteine and 4,5-dihydroxy-2,3-pentanedione (DPD) by the enzyme LuxS (or S-ribosylhomocysteinase). 3 DPD is in equilibrium with its cyclic hemiketal A and forms several QS molecules, which function as bacterial interspecies signaling molecules called autoinducers 2 (AI-2), and are detected by a wide range of bacteria. [4] [5] [6] The (2S,4S)-isomer of the hemiketal A undergoes complexation with borate to form a furanosyl borate diester as a distinct AI-2. 7 Recent chemical synthesis of the unstable DPD and their analogues has made it possible to assess the complexation properties of DPD with borate and provided DPD samples for investigation of AI-2-regulated processes. [8] [9] [10] [11] [12] [13] [14] [15] QS regulates many crucial bacterial functions such as symbiosis, virulence, antibiotic production, biofilm forma-tion. [16] [17] [18] [19] Therefore, proteins involved in QS including LuxS are being pursued as targets for designing novel antibacterial agents.
LuxS is a small metalloenzyme containing a Fe 2+ ion coordinated by His-54, His-58, Cys-126, and a water molecule. The native enzyme is unstable under aerobic conditions, but substitution of Co 2+ for Fe 2+ gives a highly stable variant with wild-type catalytic activity. 20, 21 In the proposed catalytic mechanism of LuxS, the metal ion acts as a Lewis acid and catalyzes two consecutive aldoseketose (C1?C2) and ketose-ketose (C2?C3) isomerization steps and the b-elimination of Hcy from a 3-keto intermediate to give DPD. [22] [23] [24] Cleavage of the C5-S thioether bond of SRH by LuxS is mechanistically distinct from the reversible reaction catalyzed by SAH hydrolase, which cleaves the equivalent thioether bond in SAH. The latter process is initiated by oxidation of the C3 0 alcohol of SAH with an NAD + cofactor to give a 3 0 -keto intermediate that undergoes b-elimination of Hcy. 25, 26 Recently, Zhou and co-workers designed two substrate analogues, the S-(anhydroribosyl)-L-homocysteine (B) and S-(homoribosyl)-L-cysteine (C) compounds ( Fig. 2) . The initial mechanistic step was prevented by B, and the final step by C. 27 Pei and coworkers 28 prepared a series of structural analogues of the enediolate intermediates, in which the unstable enediolate moiety was replaced with a stable hydroxamate group. Among them, stable isostere D inhibited LuxS at submicromolar concentrations (K I = 0.72 lM). The ribosyl and xylosylhomocysteines in which the carbon-5 and sulfur atoms were replaced by a vinyl or (fluoro)vinyl unit did not show significant inhibition of LuxS. 29 We now describe the synthesis and evaluation of several carbon-3 0968-0896/$ -see front matter Ó 2009 Elsevier Ltd. All rights reserved. doi:10.1016/j.bmc.2009.07.057 modified SRH analogues that lack a hydroxyl group which can be converted into an enol. These compounds act as mechanism-based inhibitors of LuxS and could impede the production of autoinducers of type 2, and disrupt quorum sensing and cell-cell communication in bacteria.
Results and discussion

Chemistry
We initially targeted 3-deoxy-SRH analogue 10 because it cannot undergo the second enolization step to produce the 3-keto intermediate. 3, 22 Treatment of diacetone 3-deoxyglucose 30 with periodic acid selectively removed the 5,6-O-isopropylidene group and oxidatively cleaved the resulting vicinal 5,6-diol 31 to give the corresponding 5-aldehyde, which was reduced with NaBH 4 to give 3-deoxy furanoside 1 (Scheme 1). Mesylation at C5, displacement with thiolate derived from D/L-homocysteine, 32 and treatment with aqueous trifluoroacetic acid gave the desired S-(3-deoxyribosyl)homocysteine 10 (a/b, 1:3; 25% from 1).
Next, the 3-O-methyl xylo-(11) and ribofuranosyl analogues (12) were prepared as potential LuxS inhibitors, because the 3methoxy group was expected to prevent the second enolization step as well. We were also interested to see whether the LuxS active site can tolerate both R and S epimers at the C3 position. Thus, mesylation of l,2-O-isopropylidene-3-O-methyl-a-D-xylofuranose 2 afforded ester 5. Nucleophilic displacement with the thiolate group of D/L-homocysteine afforded thioether 8. Deprotection (TFA/H 2 O) and purification by reversed-phase HPLC gave S-(3-Omethylxylosyl)homocysteine 11 as a mixture of two anomers (a/ b, 1:1; 50%). S-(3-O-Methylribosyl)homocysteine 12 (a/b, 3:7) was similarly prepared from the corresponding ribose 3, except that the C5-OH group was activated by conversion into 5-O-tosylate 6 (instead of 5-O-mesylate) because treatment of the latter with Hcy/NaOH led to the hydrolysis of the mesylate and recovery of alcohol 3.
S-Xylosylhomocysteine (SXH, compound 16) was synthesized from 1,2-isopropylidene-a-D-xylofuranose 13 33 (Scheme 2). The diol of 13 was converted into cyclic sulfate 14 by treatment with thionyl chloride in the presence of Et 3 N in DCM and followed by oxidation of the resulting sulfite with RuCl 3 and NaIO 4 . The cyclic sulfate 14 was readily opened 22 with the protected L-homocysteine in the presence of BuLi in DMF to give desired thioether 15, which was converted into the target compound SXH 16 by treatment with TFA.
S-(3-Deoxy-3-fluoroxylosyl)homocysteine 21a and the corresponding glycoside 21b were prepared from the readily available diacetone 3-deoxy-3-fluoroglucose 17. 34 Thus, sequential treatment of 17 with H 5 IO 6 and NaBH 4 31 gave 3-deoxy-3-fluoro-l,2-Oisopropylidene-a-D-xylofuranose (18, 60%), which was then converted into 5-O-mesylate 19b (Scheme 3). Displacement of the mesylate group with thiolate generated from N-Boc-L-Hcy-CO 2 t-Bu (LDA/DMF) gave thioether 20b in 92% yield. It is noteworthy that the use of water soluble tris(2-carboxyethyl)phosphine for the generation of the protected homocysteine free thiol from N,N 0di(tert-butoxycarbonyl)-L-homocystine di(tert-butyl) ester not only improved the reaction yield but also simplified the purification process, as compared to the more commonly used tributyl- 22 and triethylphoshines 27 for the reduction of homocystine analogues. Deprotection (TFA followed by TFA/H 2 O) of 20b gave S-(3-deoxy-3-fluoroxylosyl)homo-cysteine 21a, which showed two sets of peaks at the 19 followed by quenching of the reaction mixture with MeOH resulted in the removal of all protection groups and the formation of methyl glycoside 21b as a 1:1.1 mixture of a/b anomers (29%) as well as small amounts of 21a (7%). Displacement of the tosylate group from 19a with D/L-homocysteinate thiolate produced 20a (9R/S, 1:1) and subsequent acid-catalyzed removal of the acetonide group afforded 21a (9R/S, 1:1; a/b, 2:3), which showed four sets of peaks at the 19 F NMR spectrum. Synthesis of 3-deoxy-3-fluoro-SRH 22 and 3-bromo-3-deoxy-SRH analogue 23 have recently been described. 35 
Inhibition of LuxS
The SRH analogues 10-12, 16, 21a, and 21b were evaluated as potential inhibitors of Bacillus subtilis LuxS. Compound value of 55 ± 6 lM (Table 1 and Fig. 3 ). We also tested whether compound 10 can act as a substrate of LuxS. In particular, we were interested in whether it could be converted into the corresponding 2-ketone intermediate in the LuxS reaction. Since the intermediate cannot be converted into DPD product due to its lack of the 3-hydroxyl group, this would provide an alternative substrate to study the detailed mechanism of the first catalytic step. The 13 On the other hand, compounds 16, 21a, and 21b all exhibited time-dependent inhibition of LuxS. Figure 4 shows the example of inhibition of Vibrio harveyi LuxS (VhLuxS) by compound 21a. Preincubation of LuxS with the inhibitor resulted in gradual loss of LuxS activity with time; the activity decrease continued for $60 min, when there was no further change in the residual activity. The compounds were also incubated with BsLuxS and the reaction mixtures were analyzed by electrospray ionization mass spectrometry to detect any covalent adduct between the enzyme and the inhibitors. We only observed signals that correspond to the unmodified BsLuxS protein, indicating that compounds 16, 21a, and 21b do not covalently modify the LuxS protein. Thus, these compounds act as slow-binding inhibitors of LuxS and their inhibition kinetics may be described by equation
where EÁI represents the initial enzyme-inhibitor complex, EÁI * is the final, tighter enzyme-inhibitor complex, K I is the equilibrium constant for the formation of the initial EÁI complex, k is the rate constant for the conversion of the EÁI complex to the tighter EÁI * complex, and K Ã I represents the dissociation constant of the EÁI * complex. The K I values were determined by initiating the enzymatic reactions with the LuxS enzyme (no preincubation), whereas the K Ã The observed slow-binding behavior of compounds 16, 21a, and 21b is very similar to that of [3-F]SRH (22) and [3-Br]SRH (23), both of which exhibited time-dependent inhibition of LuxS and their time dependency was caused by enzyme-catalyzed release of halide ions. 35 Because compounds 16 and 21a are structurally similar to 22 and 23, we hypothesize that compounds 16 and 21a may undergo similar structural changes in the LuxS active site (e.g., the formation of 2-ketone intermediate-like species). The inverted stereochemistry at the C3 position in SXH would prevent the conversion of the intermediate into products. Unfortunately, all of our attempts to isolate/detect the altered inhibitor species (I * ) failed. Thus, we cannot rule out the possibility that the observed slow-binding inhibition was caused by the conversion of EÁI into E * ÁI, where E * is LuxS in an alternative conformation induced by inhibitor binding. The origin of time dependency of glycoside 21b is less clear, as it cannot undergo ring opening and therefore any catalyzed transformation.
Conclusion
In this work, we have synthesized several SRH analogues that lack an enolizable hydroxyl group at the carbon-3 position. Their evaluation against LuxS showed that removal or methylation of the C3-OH resulted in simple competitive inhibitors of moderate potency, while inversion of the C3 stereochemistry or substitution of fluorine for C3-OH resulted in slow-binding inhibition with the improved potency. ). The white precipitate was filtered off and was washed with EtOAc (3 Â 5 mL). The combined organic layer was evaporated, and the residue was quickly dissolved in EtOH (30 mL). Sodium borohydride (115 mg, 3.0 mmol) and water (10 mL) was added until all of the sodium borohydride was dissolved. After 45 min, the reaction mixture was evaporated, and the resulting residue was dissolved in EtOAc and washed with NaHCO 3 . The organic layer was dried (Na 2 SO 4 ), evaporated and flash column chromatographed (40?60% EtOAc/hexane) to give 1 36 (217 mg, 61%).
Experimental section
3-Deoxy-l,2-O-isopropylidene-5-O-methylsulfonyl-a-Derythro-pentofuranose (4)
Triethylamine (125 lL, 90.9 mg, 0.9 mmol) and CH 3 SO 2 Cl (35 lL, 51.3 mg, 0.45 mmol) were added to a stirred solution of 1 (52 mg, 0.3 mmol) in anhydrous CH 2 Cl 2 (10 mL) under N 2 at 0°C. After 10 min, the reaction mixture was partitioned (NaHCO 3 / H 2 O//CHCl 3 ), and the organic layer was washed (brine), dried (Na 2 SO 4 ) and evaporated to yield 4 37 (73 mg, 97%) of sufficient purity to be used in the next step: 1 
l,2-O-Isopropylidene-3-O-methyl-5-O-methylsulfonyl-a-Dxylofuranose (5)
Treatment of 2 38 (50 mg, 0.25 mmol; prepared in 77% yield by dehomologation 31 of diacetone 3-O-methylglucose 39 
l,2-O-Isopropylidene-3-O-methyl-5-O-p-toluenesulfonyl-a-D-ribofuranose (6)
TsCl (93 mg, 0.49 mmol) was added to a stirred solution of 3 40 (90 mg, 0.45 mmol; prepared in 67% yield by dehomologation 31 of diacetone 3-O-methylallose 40 as described for 1) in pyridine (1 mL) at 0°C. After 12 h, an additional TsCl (93 mg, 0.49 mmol) was added and the stirring was continued for 8 h. Pyridine was evaporated/coevaporated with toluene (3Â), and the residue was dissolved in EtOAC and washed with NaHCO 3 and NaCl. The organic layer was evaporated and column chromatographed (hexane/ EtOAc, 1:1) to give 6 40 (117 mg, 72%) of sufficient purity to be used in the next step: 1 Compound 4 (45.6 mg, 0.18 mmol) was added to 1 M NaOH/ H 2 O (5 mL) and degassed with N 2 for 30 min. D/L-Homocysteine (36.5 mg, 0.27 mmol) was then added, and the suspension was heated to 60°C. After 12 h, the reaction mixture was cooled to room temperature, neutralized with dilute HCl to pH $ 7 and washed with EtOAc (3Â). The water layer was evaporated and purified by HPLC (25% CH 3 To a stirred solution of diol 13 33 (0.4 g, 2.11 mmol) in CH 2 Cl 2 (12 mL) were added TEA (1.2 mL, 8.42 mmol) and SOCl 2 (2 M/ DCM; 2.1 mL, 4.22 mmol) at À78°C under argon atmosphere. The mixture was allowed to warm to 0°C and stirred until the reaction was completed (1 h). The reaction mixture was diluted in DCM (50 mL), washed with H 2 O (20 mL), dried over MgSO 4 , and concentrated to dryness. The residue was dissolved in CCl 4 (6 mL) and CH 3 CN (6 mL). To the resulting solution was added H 2 O (9 mL) followed by RuCl 3 hydrate (15 mg) and NaIO 4 (0.9 g, 4.22 mmol) at 0°C. The mixture was stirred for 2 h, diluted in EtOAc (50 mL), washed with H 2 O (20 mL), dried over MgSO 4 , and concentrated in reduced pressure. The crude product was purified by silica gel chromatography (EtOAc/hexane, 1:2) to afford the cyclic sulfate 14 (0.39 g, 74%) as a white solid: 1 To a solution of BocNH-CH(CH 2 CH 2 SH)-CO 2 tBu (1.1 g, 3.77 mmol) in DMF (15 mL) was added BuLi (2.5 M/hexane; 0.9 mL, 2.26 mmol) at 0°C under argon atmosphere. After stirring for 5 min, a solution of cyclic sulfate 14 (0.38 g, 1.51 mmol) dissolved in DMF (10 mL) was added. The mixture was stirred for 4 h, diluted with EtOAc (75 mL), washed with H 2 O (25 mL) and brine (25 mL). The organic layer was dried over MgSO 4 and concentrated to dryness. The residue was dissolved in THF (3 mL) and concentrated H 2 SO 4 (2 lL) and H 2 O (2 lL) were added at 0°C.
The mixture was stirred for 1 h at 0°C and then partitioned between EtOAc (100 mL) and 5% NaHCO 3 solution (40 mL). The organic layer was collected, washed with H 2 O (20 mL) and brine (20 mL), dried over MgSO 4 and concentrated under vacuum. The crude product was purified by silica gel chromatography (EtOAc/ hexane, 2:3) to afford alcohol 15 (0.47 g, 67%) as a white solid: Treatment of 17 34 (75 mg, 0.29 mmol) with H 5 IO 6 (77 mg, 0.34 mmol) and NaBH 4 (16.5 mg, 0.43 mmol), as described for 1, followed by flash column chromatography (EtOAc/hexane, 1:1) gave 18 (39 mg, 71%) with data as reported: 41 19 F NMR d À208.66 (ddd, J = 11.2, 30.1, 50.4 Hz). A solution of 19a (18.5 mg, 0.05 mmol) in 2 M NaOH/H 2 O-EtOH solution (4 mL, 1:1) was degassed with N 2 for 30 min. D/L-Homocysteine (11 mg, 0.08 mmol) was added, and the solution was heated to 60°C. After 36 h, the reaction mixture was cooled to room temperature, neutralized with concd HCl and washed with EtOAc (3Â). The water layer was evaporated and purified by HPLC (5% CH 3 Step a: H 2 O (0.24 mL) and tris(2-carboxyethyl)phosphine hydrochloride (88 mg, 0.31 mmol) were added to a stirred solution of N,N 0 -di(tert-butoxycarbonyl)-L-homocystine di(tert-butyl) ester (160 mg, 0.28 mmol) in anhydrous DMF (2.4 mL) at ambient temperature under Ar atmosphere. After 32 h, the reaction mixture [TLC (EtOAc/hexane, 2:8) showed conversion of disulfide (R f 0.55) into thiol (R f 0.65)] was partitioned between EtOAc, and saturated NaHCO 3 /H 2 O. After separation, the aqueous layer was extracted with EtOAc, and the combined organic layer was washed with brine, dried (Na 2 SO 4 ), and concentrated to give N-tert-butoxycarbonyl-L-homocysteine tert-butyl ester 22 (159 mg, 99%) as colorless oil of sufficient purity to be directly used in next step.
Step b: A freshly prepared homocysteine (80 mg, 0.275 mmol) was dissolved in anhydrous DMF (0.5 mL), and was stirred under a vigorous stream of argon for 10 min at 0°C (ice-bath). Next, a solution of LDA (138 lL, 2.0 M/THF-heptane) was added dropwise and after an additional 10 min 19b (31 mg, 0.115 mmol) in anhydrous DMF (0.5 mL) was added via syringe. After 15 min, ice-bath was removed and the reaction mixture was stirred for 28 h at ambient temperature (TLC showed consumption of 19b). Ice-cold saturated NH 4 Cl/H 2 O was added and the resulting suspension was diluted with EtOAc. The organic layer was separated and the aqueous layer was extracted with EtOAc. The combined organic layer was washed with brine, dried (Na 2 SO 4 ) and was evaporated to give 94 mg of yellowish oily residue. This crude product was column chromatographed on silica gel (hexane/EtOAc, 4:1) to give 20b as an colorless oil (49 mg, 92%): 1 Treatment of 20a (6 mg, 0.02 mmol; 9R/S, $1:1) with TFA/H 2 O (9:1, 5 mL), as described for 10, and purification by HPLC (preparative RP-C18 column, 5% CH 3 CN/H 2 O for 45 min at 2.5 mL/min; t R = 16.5 min) gave 21a (3 mg, 55%; 9R/S, $1:1, a/b, $2:3): 19 F NMR (D 2 O) d À202.41 (ddd, J = 18.7, 25.4, 52.1 Hz, 0.2F; a, 21a-9S), À202.38 (ddd, J = 18.7, 25.4, 52.1 Hz, 0.2F; a, 21a-9R), À200.55 (ddd, J = 12.6, 28.0, 50.6 Hz, 0.3F; b, 21a-9S), À200.52 (ddd, J = 12.6, 28.0, 50.6 Hz, 0.3F; b, 21a-9R); 1 H NMR spectra as reported below for 21a-9S; MS (APCI) m/z 270 (MH + ); HRMS (LCT-ESI) m/z calcd for C 9 
